User‐only design to assess drug effectiveness in clinical practice: application to bisphosphonates and secondary prevention of fractures
- 9 June 2014
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 23 (8) , 859-867
Abstract
Purpose: Different strategies applicable to control for confounding by indication in observational studies were compared in a large population‐based study regarding the effect of bisphosphonates (BPs) for secondary prevention of fractures.Methods: The cohort was drawn from healthcare utilization databases of 13 Italian territorial units. Patients aged 55 years or more who were hospitalized for fracture during 2003–2005 entered into the cohort. A nested case‐control design was used to compare BPs use in cohort members who did (cases) and who did not experience (controls) a new fracture until 2007 (outcome). Three designs were employed: conventional‐matching (D1), propensity score‐matching (D2), and user‐only (D3) designs. They differed for (i) cohort composition, restricted to patients who received BPs straight after cohort entry (D3); (ii) using propensity score for case‐control matching (D2); and (iii) compared groups of BPs users versus no users (D1 and D2) and long‐term versus short‐term users (D3).Results: Bisphosphonate users had odds ratios (95% confidence interval) of 1.20 (1.01 to 1.44) and 0.95 (0.74 to 1.24) by applying D1 and D2 designs, respectively. Statistical evidence that long‐term BPs use protects the outcome onset with respect to short‐term use was observed for user‐only design (D3) being the corresponding odds ratio (95% confidence interval) 0.64 (0.44 to 0.93).Conclusions: User‐only design yielded closer results to those seen in RCTs. This approach is one possible strategy to account for confounding by indication. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
Funding Information
- AIFA - the Italian Medicines Agency (FARM06R9YY)
This publication has 24 references indexed in Scilit:
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Population‐based study of the effectiveness of bone‐specific drugs in reducing the risk of osteoporotic fracturePharmacoepidemiology and Drug Safety, 2008
- Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial ResultsMedical Care, 2007
- Developments in Post-marketing Comparative Effectiveness ResearchClinical Pharmacology & Therapeutics, 2007
- Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled TrialThe Journal of Clinical Endocrinology & Metabolism, 2000
- Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical TrialJournal of Bone and Mineral Research, 1998
- Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly WomenThe Journal of Clinical Endocrinology & Metabolism, 1997
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Reducing Bias in Observational Studies Using Subclassification on the Propensity ScoreJournal of the American Statistical Association, 1984
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983